secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000784199-25-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M
-----------------------------------------------------------------------

- Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.
- Q4 net loss $(16.5)M ($0.39/share) vs loss $(4.0)M prior year; Adjusted EBITDA $17.6M (+15%).
- FY2024 revenue $388.5M (+10% GAAP), net loss $(13.4)M vs $(30.7)M in 2023; Adjusted EBITDA $71.3M (+32%).
- FDA granted Humanitarian Device Exemption for AMDS; second PMA module submitted; clinical data showed 50% mortality reduction.
- FY2025 revenue guidance $420-435M (10-14% constant currency growth); adjusted EBITDA $84-91M (18-28% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419925000012/0000784199-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419925000012/aort-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000784199-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer